LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Neogen® to Participate in the 44th Annual William Blair Growth Stock Conference

May 30, 2024 | Last Trade: US$5.64 0.11 -1.91

LANSING, Mich., May 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the 44th Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 4, 2024.

John Adent, Neogen's President and Chief Executive Officer, will present at 8:00 a.m. Central Time.

Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 4. To access them, along with the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Contact

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page